Cadherin 2 Antibody / CDH2 / N-Cadherin / CD325

Overview

Cadherin 2 Antibody / CDH2 / N-Cadherin / CD325 is a research-use primary antibody intended for detection of CDH2 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone CDH2/1573, isotype Mouse IgG1, kappa. Applications listed for this product include IHC-P. Reported/annotated localization context: Cell surface, cytoplasmic. Species reactivity (as provided): Human, Mouse.

Key elements and design rationale

• Target: CDH2 (Cadherin 2) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
• Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
• Antibody identity: Mouse, Monoclonal (mouse origin), clone CDH2/1573, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
• Localization: Cell surface, cytoplasmic — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
• Product notes (from provided description): Recognizes a protein of ~140kDa, identified as N-Cadherin (NCAD), also known as Cadherin 2, CDH2 and CD325. Cadherin 2 is a 140 kDa protein belonging to a family of transmembrane molecules that mediate calcium-dependent intercellular adhesion. Cadherins are involved in controlling morphogenetic movements during development and regulate cell surface adhesion through homotypic adhesion with the same cadherin species. Expression of Cadherin 2 has been reported on a variety of normal tissues including neuronal, endothelial and muscle cells, and a subpopulation of early hematopoietic progenitor cells. Results aid in the classification of malignant non-carcinomatous neoplasms including mesotheliomas, chordomas, synovial sarcomas, malignant melanomas, epithelioid sarcomas, epithelioid angiosarcomas, clear cell sarcomas as well as serous and endometrioid tumors of the ovary have been demonstrated to be Cadherin 2 positive, whereas mucinous tumors are negative. Other Cadherin 2-positive neoplasms include renal cell carcinomas and some variant breast tumors, including medullary breast carcinomas and sarcomatoid metaplastic breast carcinomas.

Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.

Biological background

In this catalog, CDH2 is positioned within ECM & Cell Adhesion, Immunology & Inflammation, Tumor, Renal disease research contexts. Localization annotations (e.g., Cell surface, cytoplasmic) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.

Research relevance and current trends

• Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
• Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
• Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.

Common research applications

• IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
• Typical workflow themes: IHC on FFPE tissue, ELISA binding assay, Specificity controls.
• Workflow notes: Detect CDH2 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to CDH2 peptide/protein by ELISA with dilution series (include blanks), Confirm specificity using KO/KD or peptide co…

When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.

Notes for experimental interpretation

• Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
• Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
• Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.

Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.